Working Memory in Patients with Major Depressive Disorder

Yasuhiro Kaneda

Department of Psychiatry, Iwaki Clinic, Tokushima, Japan.

DOI: 10.4236/psych.2012.329115                

Abstract

Objective: Patients with major depressive disorder (MDD) have been reported to perform less well in neurocognitive tests than normal control subjects. The author tested the hypotheses that verbal working memory (WM) is predictive of the functional outcome in patients with MDD. Methods: In this naturalistic longitudinal study, the subjects consisted of 22 adult outpatients receiving paroxetine as antidepressant therapy. Functional outcome was rated on a scale of 0 (non-impaired) to 3 (severely impaired). Results: 1) At 12 weeks, nine of the 22 patients currently experiencing MDD exhibited full remission; 2) significantly decreased 7-item Hamilton Rating Scale for Depression (HAM-D7) scores were observed during the 12-week study period, while Digit Sequencing Task (DST) scores increased significantly; 3) at baseline, functional outcomes correlated significantly with HAM-D7 scores, but, at 12 weeks, correlated significantly with both HAM-D7 and DST scores. Furthermore, when looking at only patients in full or partial remission (mild depression), functional outcome correlated more strongly with DST than with HAM-D7 scores. Conclusions: A deficit of verbal WM correlated with the functional outcome after treatment in pa- tients with MDD. Antidepressant therapy with paroxetine might contribute to improvement of verbal WM.

Keywords

Depression; Functional Outcome; Paroxetine; Symptomatlogy; Working Memory

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association.
[2]	Biringer, E., Mykletun, A., Sundet, K., Kroken, R.,Stordal, K. I.,& Lund, A. (2007). A longitudinal analysis of neurocognitive function in unipolar depression. Journal of Clinical and Experimental Neuropsychology, 29, 879-891. doi:10.1080/13803390601147686
[3]	Cassano, G. B., Puca, F., Scapicchio, P. L., & Trabucchi, M. (2002). Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. The Journal of Clinical Psychiatry, 63, 396-402. doi:10.4088/JCP.v63n0504
[4]	Gorenstein, C., de Carvalho, S. C., Artes, R., Moreno, R. A., & Marcour- akis, T. (2006). Cognitive performance in depressed patients after chronic use of antidepressants. Psychopharmacology, 185, 84-92. doi:10.1007/s00213-005-0274-2
[5]	Gualtieri, C. T., Johnson, L. G., & Benedict, K. B. (2006). Neurocognition in depression: Patients on and off medication versus healthy comparison subjects. The Journal of neuropsychiatry and clinical neurosciences, 18, 217-225. doi:10.1176/appi.neuropsych.18.2.217
[6]	Gualtieri, C. T., & Morgan, D. W. (2008). The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: An unaccounted source of variance in clinical trials. The Journal of Clinical Psychiatry, 69, 1122-1130. doi:10.4088/JCP.v69n0712
[7]	Hindmarch, I. (2009). Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. International Journal of Clinical Practice, 63, 1085-1094. doi:10.1111/j.1742-1241.2009.02085.x
[8]	Kaneda, Y. (2009a). Verbal working memory and functional outcome in patients with unipolar major depressive disorder. World Journal of Biological Psychiatry, 10, 591-594. doi:10.1080/15622970903183705
[9]	Kaneda, Y. (2009b). Verbal working memory impairment in patients with current episode of unipolar major depressive disorder and in remission. Clinical Neuropharmacology, 32, 346-347. doi:10.1080/15622970903183705
[10]	Kaneda, Y., Jayathilak, K., & Meltzer, H. (2010). Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: Cognitive impairment and clozapine treatment. Psychiatry Research, 178, 57-62. doi:10.1016/j.psychres.2009.04.001
[11]	Kaneda, Y., Jayathilak, K., & Meltzer, H. Y. (2009). Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function. Psychiatry Research, 169, 178-179. doi:10.1016/j.psychres.2008.08.003
[12]	Keefe, R. S., Goldberg, T. E., Harvey, P. D., Gold, J. M., Poe, M. P., & Coughenour, L. (2004). The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 68, 283-297. doi:10.1016/j.schres.2003.09.011
[13]	Kennedy, N., Foy, K., Sherazi, R., McDonough, M., & McKeon, P. (2007). Long-term social functioning after depression treated by psychiatrists: A review. Bipolar Disorders, 9, 25-37. doi:10.1111/j.1399-5618.2007.00326.x
[14]	Kitagawa, N., & Koyama, T. (2009). Assessment of neurocognitive function in mood disorders and its utilization to clinical practice. Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry), 38, 437-445.
[15]	Malone, D. C. (2007). A budget-impact and cost-effectiveness model for second-line treatment of major depression. Journal of Managed Care Pharmacy, 13, S8-18.
[16]	Marcos, T., Portella, M. J., Navarro, V., Gasto, C., Rami, L., Lazaro, L., & Salamero, M. (2005). Neuropsychological prediction of recovery in late-onset major depression. International Journal of Geriatric Psy- chiatry, 20, 790-795. doi:10.1002/gps.1363
[17]	McIntyre, R. S., Konarski, J. Z., Mancini, D. A., Fulton, K. A., Parikh, S. V., Grigoriadis, S., Grupp, L. A., Bakish, D., Filteau, M. J., Gorman, C., Nemeroff, C. B., & Kennedy, S. H. (2005). Measuring the severity of depression and remission in primary care: Validation of the HAMD-7 scale. Canadian Medical Association Journal, 173, 1327-1334. doi:10.1503/cmaj.050786
[18]	Nebes, R. D., Pollock, B. G., Houck, P. R., Butters, M. A., Mulsant, B. H., Zmuda, M. D., & Reynolds III, C. F., (2003). Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine. Journal of Psychiatric Research, 37, 99-108. doi:10.1016/S0022-3956(02)00085-7
[19]	Porter, R. J., Gallagher, P., Thompson, J. M., & Young, A. H. (2003). Neurocognitive impairment in drug-free patients with major depresssive disorder. The British Journal of Psychiatry, 182, 214-220. doi:10.1192/bjp.182.3.214
[20]	Reppermund, S., Ising, M., Lucae, S., & Zihl, J. (2009). Cognitive impairment in unipolar depression is persistent and non-specific: Further evidence for the final common pathway disorder hypothesis. Psychological Medicine, 39, 603-614. doi:10.1017/S003329170800411X
[21]	Rose, E. J., & Ebmeier, K. P. (2006). Pattern of impaired working memory during major depression. Journal of Affective Disorders, 90, 149-161. doi:10.1016/j.jad.2005.11.003
[22]	Stewart, S. A. (2005). The effects of benzodiazepines on cognition. The Journal of Clinical Psychiatry, 66, 9-13.
[23]	Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Attiullah, N., & Boerescu, D. (2006). How should remission from depression be defined? The depressed patient’s perspective. The American Journal of Psychiatry, 163, 148-150. doi:10.1176/appi.ajp.163.1.148